Archive
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19

— Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19
— Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional benefits
— Results have been published in The Lancet Regional Health – Europe
MetrioPharm AG, a biotech company developing drugs for inflammatory and infectious diseases, announced today that results from its clinical trial CT-05 in hospitalized patients with moderate to severe COVID-19 have been published in the renowned journal The Lancet Regional Health – Europe.
